Macaques were given a single subcutaneous (SC) bolus dose in the back mid-scapular region of 25.0 mg/kg LPV, 7.0 mg/kg RTV, and 10.6 mg/kg TFV, either as TLC-ART101 or free ARV formulation. In four animals dosed with TLC-ART101, blood was collected at 0, 0.25, 0.5, 1, 3, 5, 8, 24, 48, 120, 168, 192, and 336 hr for full PK profiling; in another four animals designated for lymph node biopsy, blood was only collected at 0, 0.5, and 24 hr. In three animals dosed with the free ARV formulation, blood was collected at 0, 0.5, 8, 12, 18, and 24 hr. LPV, RTV, and TFV concentrations in plasma were simultaneously analyzed using a validated LC-MS/MS method [20 ]. The following descriptive PK parameters were estimated using the non-compartmental analysis module in Phoenix v6.4 (Certara, Mountain View, CA, USA): AUC, area under the plasma drug concentration-time curve; CL/F, apparent total clearance; MBRT, mean body residence time; t1/2, apparent terminal plasma drug half-life.
Phoenix v 6
Manufactured by Certara
Sourced in United States
Phoenix (v. 6) is a pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation software. It provides a comprehensive platform for modeling and simulation of drug behavior in the body. The software supports a wide range of modeling approaches and data analysis techniques.
Automatically generated - may contain errors
Lab products found in correlation
3 protocols using phoenix v 6
1
Pharmacokinetics of Long-Acting ARV Formulation
2
Non-compartmental Pharmacokinetic Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The AUC from time zero to infinity (AUCinf) and maximum plasma concentration (Cmax) were determined via noncompartmental analysis using Phoenix (v. 6, Certara USA, Princeton, NJ) for all analytes. For this analysis, actual plasma sampling times were utilized and a minimum of 3 points were used to define the terminal phase. All plasma concentrations max and AUCinf ratio (AUC GMR or AUCR) with 90% confidence interval (CI) was calculated.
3
Noncompartmental Pharmacokinetic Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The AUCinf and Cmax were determined via noncompartmental analysis using Phoenix (v. 6, Certara USA, Princeton, NJ) for all analytes. For this analysis, actual plasma sampling times were utilized and a minimum of 3 points were used to define the terminal phase. All plasma concentrations inf ratio (AUCinf GMR or AUCR) with 90% CI was calculated.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!